MiNK Therapeutics, Inc. (INKT) Misses Q4 EPS by 1c

MiNK Therapeutics, Inc. (NASDAQ: INKT) reported Q4 EPS of ($0.16), $0.01 worse than the analyst estimate of ($0.15).

For earnings history and earnings-related data on MiNK Therapeutics, Inc. (INKT) click here.

You May Also Be Interested In

• Wall Street sees Muse as Meta’s next big catalyst after Connect event
• HawkEye 360 wins $18M in Middle East contract awards
• SYNNEX Corp. (SNX) Tops Q3 EPS by $1.04, Beats on Revenue; Offers Q4 Guidance